Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

183.55USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$183.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,173,405
52-wk High
$201.23
52-wk Low
$152.16

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

CORRECTED-Novartis readies to auction U.S. generic pills business -sources

Feb 16 Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

16 Feb 2018

BRIEF-Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of Blincyto

* AMGEN ANNOUNCES FDA ADVISORY COMMITTEE MEETING TO REVIEW POTENTIAL NEW USE OF BLINCYTO® (BLINATUMOMAB)

15 Feb 2018

Amgen quarterly profit misses, 2018 EPS outlook ahead of Street view

Feb 1 Amgen Inc on Thursday reported fourth-quarter profit well below Wall Street estimates, as a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses hit results.

02 Feb 2018

BRIEF-Amgen Inc Q4 Loss Per Share $5.89

* AMGEN QTRLY LOSS PER SHARE $5.89; QTRLY ADJUSTED EARNINGS PER SHARE $2.89; QTRLY REVENUE $5.80 BILLION, DOWN 3 PERCENT

02 Feb 2018

BRIEF-Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To Kyprolis Label

* AMGEN RECEIVES CHMP POSITIVE OPINION TO ADD UPDATED OVERALL SURVIVAL DATA TO KYPROLIS® (CARFILZOMIB) LABEL Source text for Eikon: Further company coverage:

30 Jan 2018

BRIEF-Amgen Reports Aimovig Met All Primary, Secondary Endpoints

* AMGEN REPORTS AIMOVIG™ (ERENUMAB) MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS

23 Jan 2018

BRIEF-European Commission Approves Amgen, Allergan's Mvasi

* EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® (BIOSIMILAR BEVACIZUMAB) FOR THE TREATMENT OF CERTAIN TYPES OF CANCER

19 Jan 2018

BRIEF-FDA Approves Addition Of Overall Survival Data To Kyprolis Label

* FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLIS® (CARFILZOMIB) LABEL

18 Jan 2018

BRIEF-Biocartis And Amgen Sign New Agreement

* REG-BIOCARTIS GROUP NV: BIOCARTIS AND AMGEN SIGN NEW COMPANION DIAGNOSTIC AGREEMENT FOR NOVEL ONCOLOGY COMPOUND

09 Jan 2018

FDA expands use of Amgen's blockbuster drug

Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma.

05 Jan 2018

Earnings vs. Estimates